By Nancy Lapid
(Reuters) – Following is an overview of some of the latest research on the new coronavirus and efforts to find treatments and vaccines for COVID-19, the disease caused by the virus.
The vaccine protects COVID-19 survivors against variants
In two COVID-19 survivors, the Pfizer / BioNTech mRNA vaccine protects not only against the original strain of the virus, but also against alarming variants, two studies show. Researchers in the United Kingdom analyzed the immune response after a single dose of the vaccine in 51 people, including 25 people previously infected with an early version of the new coronavirus. Survivors have shown enhanced antibody responses to newer, more infectious variants, first seen in the UK and South Africa, while people who have not been previously infected do not produce antibodies that can neutralize the variants, according to a report. on Friday in Science. Separately, American scientists studied 30 people after two doses of the vaccine. Immune responses were 3.4-fold better at neutralizing coronavirus in the 1
Related: Vaccines reduce transmission by half: a study
COVID-19 spike protein damages blood vessels
The “spike” proteins that the coronavirus uses to help it penetrate cells also cause other damage, according to a new study that sheds light on the many ways in which COVID-19 attacks organs other than the lungs. The thorn proteins themselves cause direct damage to the cells that line the blood vessels, scientists found in experiments with test tubes using a constructed version of the cells with thorns and mucous membranes derived from mice. Once attached to the ACE2 protein on healthy cells, the spike disrupts ACE2 signaling to mitochondria – the energy-generating structures of the cell – causing mitochondria to be damaged, researchers said Friday in Circulation Research. COVID-19 is indeed a disease of blood vessels, said co-author Uri Manor of the Salk Institute for Biological Research in La Jolla, California. New findings may help explain the blood clots associated with COVID-19. They could also explain “why some people have strokes and why some people have problems with other parts of the body,” Manor said. “What they have in common is that they all have a vascular basis.” (https://bit.ly/3eIhuNF)
Cancer research in the United States fell sharply during a pandemic
Nearly 10 million screenings for three common cancers have been missed in the United States due to the COVID-19 pandemic, a new study shows. Researchers comparing monthly spring and summer screening rates in 2020 with rates in 2018 and 2019 found a 90.8% drop in breast cancer screening, a 79.3% drop in colon cancer screening and 63.4% in prostate cancer screening in April 2020 alone, researchers reported Thursday at JAMA Oncology. “There was a deficit of 9.4 million in screening for the three major cancers in the United States, most likely related to the COVID-19 pandemic,” said co-author Dr. Ronald Chen of the University of Kansas Cancer Center. You are. “This is a deficit that we need to make up for in 2021.” Some good news from the study: telehealth visits appear to be linked to the return of cancer screenings to the rails. Healthcare teams that could reach patients through telehealth “were able to come up with a screening plan,” Chen said. “This underscores the importance of telehealth and the importance of continuing it after the end of the pandemic.” (https://bit.ly/3e3yTS7)
Open https://tmsnrt.rs/3c7R3Bl in an external browser for the Reuters schedule for vaccines under development.
(Report by Nancy Lapid and Linda Carroll; Edited by Bill Bercrot)